Rhenman & Partners Asset Management Ab Viking Therapeutics, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $1.01 Billion
- Q2 2024
A detailed history of Rhenman & Partners Asset Management Ab transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 115,000 shares of VKTX stock, worth $8.34 Million. This represents 0.6% of its overall portfolio holdings.
Number of Shares
115,000
Previous 145,000
20.69%
Holding current value
$8.34 Million
Previous $11.9 Million
48.73%
% of portfolio
0.6%
Previous 1.16%
Shares
8 transactions
Others Institutions Holding VKTX
# of Institutions
460Shares Held
65.6MCall Options Held
6.24MPut Options Held
2.97M-
Vanguard Group Inc Valley Forge, PA10.1MShares$732 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$437 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$372 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.25MShares$163 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$135 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $5.56B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...